AIMS/HYPOTHESIS: The adipokine adiponectin has insulin-sensitising, anti-atherogenic and anti-inflammatory properties. Recently, the genes for mouse and human adiponectin receptor-1 (ADIPOR1) and -2 (ADIPOR2) have been cloned. The aim of this study was to investigate whether genetic variants of the genes encoding ADIPOR1 and ADIPOR2 play a role in human metabolism. MATERIALS AND METHODS: We screened ADIPOR1 and ADIPOR2 for polymorphisms and determined their association with glucose metabolism, lipid metabolism, an atherogenic lipid profile and inflammatory markers in 502 non-diabetic subjects. A subgroup participated in a longitudinal study; these subjects received diet counselling and increased their physical activity. RESULTS: We identified six variants of ADIPOR1 and seven variants of ADIPOR2. A single-nucleotide polymorphism (SNP) in the putative promoter region 8503 bp upstream of the translational start codon (-8503 G/A) of ADIPOR1 (frequency of allele A=0.31) was in almost complete linkage disequilibrium with another SNP (-1927 T/C) in intron 1. Subjects carrying the -8503 A and -1927 C alleles had lower insulin sensitivity, as estimated from a 75 g OGTT (p=0.04) and determined during a euglycaemic clamp (n=295, p=0.04); they also had higher HbA(1)c levels (p=0.02) and, although the difference was not statistically significant, higher liver fat (n=85, determined by proton magnetic resonance spectroscopy, p=0.056) (all p values are adjusted for age, sex and percentage of body fat). In the longitudinal study (n=45), the -8503 A and -1927 C alleles were associated with lower insulin sensitivity (p=0.03) and higher liver fat (p=0.02) at follow-up compared with the -8503 G and -1927 T alleles, independently of basal measurements, sex and baseline and follow-up percentage of body fat. CONCLUSIONS/ INTERPRETATION: The present findings suggest that the -8503 G/A SNP in the promoter or the -1927 T/C SNP in intron 1 of ADIPOR1 may affect insulin sensitivity and liver fat in humans.
AIMS/HYPOTHESIS: The adipokine adiponectin has insulin-sensitising, anti-atherogenic and anti-inflammatory properties. Recently, the genes for mouse and humanadiponectin receptor-1 (ADIPOR1) and -2 (ADIPOR2) have been cloned. The aim of this study was to investigate whether genetic variants of the genes encoding ADIPOR1 and ADIPOR2 play a role in human metabolism. MATERIALS AND METHODS: We screened ADIPOR1 and ADIPOR2 for polymorphisms and determined their association with glucose metabolism, lipid metabolism, an atherogenic lipid profile and inflammatory markers in 502 non-diabetic subjects. A subgroup participated in a longitudinal study; these subjects received diet counselling and increased their physical activity. RESULTS: We identified six variants of ADIPOR1 and seven variants of ADIPOR2. A single-nucleotide polymorphism (SNP) in the putative promoter region 8503 bp upstream of the translational start codon (-8503 G/A) of ADIPOR1 (frequency of allele A=0.31) was in almost complete linkage disequilibrium with another SNP (-1927 T/C) in intron 1. Subjects carrying the -8503 A and -1927 C alleles had lower insulin sensitivity, as estimated from a 75 g OGTT (p=0.04) and determined during a euglycaemic clamp (n=295, p=0.04); they also had higher HbA(1)c levels (p=0.02) and, although the difference was not statistically significant, higher liver fat (n=85, determined by proton magnetic resonance spectroscopy, p=0.056) (all p values are adjusted for age, sex and percentage of body fat). In the longitudinal study (n=45), the -8503 A and -1927 C alleles were associated with lower insulin sensitivity (p=0.03) and higher liver fat (p=0.02) at follow-up compared with the -8503 G and -1927 T alleles, independently of basal measurements, sex and baseline and follow-up percentage of body fat. CONCLUSIONS/ INTERPRETATION: The present findings suggest that the -8503 G/A SNP in the promoter or the -1927 T/C SNP in intron 1 of ADIPOR1 may affect insulin sensitivity and liver fat in humans.
Authors: Mirja Tiikkainen; Marjo Tamminen; Anna-Maija Häkkinen; Robert Bergholm; Satu Vehkavaara; Juha Halavaara; Kari Teramo; Aila Rissanen; Hannele Yki-Järvinen Journal: Obes Res Date: 2002-09
Authors: A E Civitarese; C P Jenkinson; D Richardson; M Bajaj; K Cusi; S Kashyap; R Berria; R Belfort; R A DeFronzo; L J Mandarino; E Ravussin Journal: Diabetologia Date: 2004-04-23 Impact factor: 10.122
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: Erik Bader; Adriana Migliorini; Moritz Gegg; Noah Moruzzi; Jantje Gerdes; Sara S Roscioni; Mostafa Bakhti; Elisabeth Brandl; Martin Irmler; Johannes Beckers; Michaela Aichler; Annette Feuchtinger; Christin Leitzinger; Hans Zischka; Rui Wang-Sattler; Martin Jastroch; Matthias Tschöp; Fausto Machicao; Harald Staiger; Hans-Ulrich Häring; Helena Chmelova; Julie A Chouinard; Nikolay Oskolkov; Olle Korsgren; Stephan Speier; Heiko Lickert Journal: Nature Date: 2016-07-11 Impact factor: 49.962
Authors: N Siitonen; L Pulkkinen; U Mager; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; J Tuomilehto; M Laakso; M Uusitupa Journal: Diabetologia Date: 2006-05-25 Impact factor: 10.122
Authors: José López-Miranda; Pablo Pérez-Martínez; Carmen Marin; Francisco Fuentes; Javier Delgado; Francisco Pérez-Jiménez Journal: J Mol Med (Berl) Date: 2006-12-15 Impact factor: 4.599
Authors: K Müssig; M Heni; C Thamer; K Kantartzis; F Machicao; N Stefan; A Fritsche; H-U Häring; H Staiger Journal: Diabetologia Date: 2009-11-29 Impact factor: 10.122
Authors: N Stefan; A Peter; A Cegan; H Staiger; J Machann; F Schick; C D Claussen; A Fritsche; H-U Häring; E Schleicher Journal: Diabetologia Date: 2008-02-20 Impact factor: 10.122
Authors: Konstantinos Kantartzis; Andreas Peter; Fausto Machicao; Jürgen Machann; Silvia Wagner; Ingmar Königsrainer; Alfred Königsrainer; Fritz Schick; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan Journal: Diabetes Date: 2009-08-03 Impact factor: 9.461